Lymphoma, Mantle-Cell: all 810 studies
Page 6 of 9. Open to participants first (149), then studies with results posted, then the rest; newest registration first within each.
- Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow TransplantationActive, not recruitingNCT03842696Phase 1/2
- BTK Inhibitor DTRMWXHS-12 in Mantle Cell LymphomaCompletedNCT03836768Phase 1
- A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)CompletedNCT03833180Phase 1
- A Disease Registry of Patients With Mantle Cell LymphomaCompletedNCT03816683
- A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHLCompletedNCT03740529Phase 1/2
- Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell LymphomaActive, not recruitingNCT03710772Phase 2
- Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell LymphomaCompletedNCT03682796Phase 1
- A Study to Evaluate the Relationship of Lenalidomide With Tumor Flare Reaction and High Tumor Burden in Participants With Relapsed or Refractory Mantle Cell LymphomaCompletedNCT03647124
- Efficacy and Safety of Chi-BEAC Combining With Auto-HSCT to Treat Aggressive Lymphoma SubjectsStatus unknownNCT03629873Phase 2
- Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell TransplantActive, not recruitingNCT03622788Phase 1/2
- Bortezomib in Combination With Ibrutinib in Ibrutinib Relapsed Mantle Cell LymphomaWithdrawnNCT03617484Phase 2
- Pacritinib in Relapsed/Refractory Lymphoproliferative DisordersTerminatedNCT03601819Phase 1
- A Pilot Investigator-Initiated Study of Ribavirin in Indolent Follicular Lymphoma and Mantle Cell LymphomaTerminatedNCT03585725Early Phase 1
- CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell LymphomaWithdrawnNCT03579927Phase 1/2
- CD19-Specific T Cells Post AlloSCTTerminatedNCT03579888Phase 1
- Rituximab, Bendamustine and Cytarabine Followed by Venetoclax in High Risk Elderly Patients With MCLCompletedNCT03567876Phase 2
- A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AMLTerminatedNCT03547115Phase 1
- Venetoclax, Lenalidomide and Rituximab in Patients With Relapsed/Refractory Mantle Cell LymphomaStatus unknownNCT03505944Phase 1/2
- A Study to Evaluate ICP-022 in Patients With R/R Mantle Cell Lymphoma (MCL)CompletedNCT03494179Phase 1/2
- Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin LymphomaActive, not recruitingNCT03479268Phase 1
- Phase II Palbociclib +Ibrutinib in Mantle Cell LymphomaActive, not recruitingNCT03478514Phase 2
- Clinical Outcomes of Chronic Lymphocytic Leukemia (CCL) and Mantle Cell Lymphoma (MCL) Participants Treated With Ibrutinib: A Medical Chart Review From IndiaCompletedNCT03476655
- Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell LymphomaCompletedNCT03440567Phase 1
- Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell ProductTerminatedNCT03436771
- A Study of Ibrutinib in the Treatment of Chronic Lymphocytic Leukemia and Mantle-cell Lymphoma in Routine Clinical PracticeCompletedNCT03425591
- Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell MalignanciesCompletedNCT03424603Phase 1
- INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)CompletedNCT03424122Phase 1
- TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin LymphomasCompletedNCT03410901Phase 1
- A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced MalignanciesCompletedNCT03329950Phase 1
- GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host DiseaseTerminatedNCT03320642Phase 1
- The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell LymphomaCompletedNCT03295240Early Phase 1
- Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell LymphomaActive, not recruitingNCT03282396Phase 2
- Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete RemissionActive, not recruitingNCT03267433Phase 3
- Blood Immunophenotyping in Staging of Indolent B-cell Lymphomas V1.0Status unknownNCT03265158
- Ibrutinib Plus Rituximab and Lenalidomide in Treating Elderly Participants With Newly Diagnosed Mantle Cell LymphomaWithdrawnNCT03232307Phase 2
- Efficacy and Safety of Obinutuzumab Preemptive Treatment at the Time of the Molecular RelapseTerminatedNCT03229382Phase 2
- Patient-Derived Xenografts in Personalizing Treatment for Patients With Relapsed/Refractory Mantle Cell LymphomaCompletedNCT03219047Early Phase 1
- First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and LymphomasCompletedNCT03188965Phase 1
- Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22Status unknownNCT03185494Phase 1/2
- A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)Active, not recruitingNCT03162536Phase 1/2
- Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL)Active, not recruitingNCT03153202Phase 1/2
- Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin LymphomaActive, not recruitingNCT03147885Phase 1/2
- Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20CompletedNCT03097770Phase 1/2
- Observational Study for Patients With Newly Diagnosed (MCL) Not Eligible for High-dose TherapyCompletedNCT03054883
- Study of Bortezomib (BTZ) Treatment on Mantle Cell Lymphoma (MCL) in Chinese ParticipantsCompletedNCT03053024
- Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid CancersTerminatedNCT03037645Phase 1/2
- Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHLCompletedNCT03019666Phase 1
- The Efficacy and Safety of Bortezomib Combined With Fludarabine and Cytarabine Treatment for Mantle Cell LymphomaStatus unknownNCT03016988Phase 2
- Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin LymphomaCompletedNCT03015896Phase 1/2
- Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid TumorsCompletedNCT03010982Phase 1
- Haploidentical BMT With Post-Transplant Cyclophosphamide and BendamustineCompletedNCT02996773Phase 1
- Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus CarriersStatus unknownNCT02991638Phase 3
- Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisPTerminatedNCT02983097Phase 1/2
- Study of Safety,Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's MacroglobulinemiaStatus unknownNCT02981745Phase 1/2
- A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCLActive, not recruitingNCT02972840Phase 3
- Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in WaldenstromActive, not recruitingNCT02952508Phase 2
- Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin LymphomaCompletedNCT02950220Phase 1
- A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's LymphomaTerminatedNCT02914938Phase 1
- Efficacy of Upfront and Maintenance Obinutuzumab in Mantle Cell Lymphoma Treated by DHAP and MRD Driven MaintenanceCompletedNCT02896582Phase 2
- PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and LymphomaStatus unknownNCT02892695Phase 1/2
- EDOCH Alternating With DHAP for New Diagnosed Younger MCLCompletedNCT02858804Phase 4
- Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and LymphomaStatus unknownNCT02851589Phase 1/2
- Trial of Bortezomib, Cytarabine, and Dexamethasone in Mantle Cell LymphomaCompletedNCT02840539Phase 2
- Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL SubjectsActive, not recruitingNCT02825836Phase 1/2
- CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and LymphomaStatus unknownNCT02819583Phase 1/2
- Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins LymphomaTerminatedNCT02793583Phase 2/3
- A Clinical Trial of Buparlisib and Ibrutinib in LymphomaCompletedNCT02756247Phase 1
- A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted AgentsCompletedNCT02745769Phase 1
- Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in LymphomaWithdrawnNCT02743546Phase 1
- A Study of Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib in Subjects With Relapsed or Refractory Mantle Cell LymphomaWithdrawnNCT02735876Phase 3
- Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell LymphomaCompletedNCT02728531Phase 1
- Anti-CD22 CAR-T Therapy for CD19-refractory or Resistant Lymphoma PatientsStatus unknownNCT02721407Phase 1
- A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCLActive, not recruitingNCT02717624Phase 1
- Competitive Transfer of αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/LymphomaStatus unknownNCT02685670Phase 1/2
- Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCLActive, not recruitingNCT02682641Phase 2
- Allo HSCT Using RIC for Hematological DiseasesCompletedNCT02661035Phase 2
- Memory-enriched CAR-T Cells Immunotherapy for B Cell LymphomaStatus unknownNCT02652910Phase 1/2
- Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin LymphomaCompletedNCT02652715Not applicable
- CD34+ Selected ASCT for Aggressive LymphomasCompletedNCT02646098Phase 2
- Ixazomib & Rituximab After Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma in RemissionActive, not recruitingNCT02632396Phase 1/2
- Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)CompletedNCT02631044Phase 1
- Study of Safety and Efficacy of BCL201 and Idelalisib in Patients With FL and MCLCompletedNCT02603445Phase 1
- Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin LymphomaCompletedNCT02568553Phase 1
- A Trial of Obinutuzumab,GDC-0199 Plus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma PatientsCompletedNCT02558816Phase 1/2
- Peptide Receptor Radionuclide Therapy With 90Y-Dotatoc in Relapsed/Refractory Diffuse Large B Cell and Mantle Cell LymphomasTerminatedNCT02488512Phase 2
- ABT-199 & Ibrutinib in Mantle Cell Lymphoma (AIM)Active, not recruitingNCT02471391Phase 2
- A Trial of Ibrutinib, Lenalidomide and Rituximab for Patients With Relapsed/Refractory Mantle Cell LymphomaCompletedNCT02460276Phase 2
- Phase IIa Study of Copanlisib in Relapsed or Refractory Mantle Cell Lymphoma (MCL)TerminatedNCT02455297Phase 2
- A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory B-cell MalignanciesTerminatedNCT02454270Phase 1
- Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell LymphomaActive, not recruitingNCT02427620Phase 2
- Optimal Dose Finding Study ABT-199 and Ibrutinib in MCLCompletedNCT02419560Phase 1
- Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell LymphomaTerminatedNCT02356458Phase 1/2
- Phase III, Randomized Trial: Lenalidomide vs Observation After Induction With Rituximab Followed by Cht and ASCT in MCL Adult PatientsStatus unknownNCT02354313Phase 3
- Observational Study of Lenalidomide in Subjects With Mantle Cell Lymphoma Who Failed Ibrutinib TreatmentCompletedNCT02341781
- Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter's TransformationWithdrawnNCT02285244Phase 2
- Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin LymphomaWithdrawnNCT02281279Phase 1/2
- Infusion of Allogeneic, 3rd Party CD19-specific T CellsWithdrawnNCT02274506Phase 1
- Trial of PCI-32765 (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell LymphomaTerminatedNCT02269085Phase 1
- Phase II of Efficacy and Toxicity of Maintenance Sub. Rituximab After Induction in Relapsed MCL and Non-eligible HSCTStatus unknownNCT02267915Phase 2
- Tissue Collection for Biomarkers Determining Resistance to IbrutinibStatus unknownNCT02267590